CTXR Fact Sheet May 21, 2021 https://ir.citiuspharma.com/presentations Market Opportunity –Critical Care/Infectious Disease: The market potential for an effective antibiotic lock therapy (“ALT”) is estimated at $750 million per year in the U.S. and is projected to reach $1.84 billion globally in 2028... Mino-Lok has the potential to change the standard of care for the management of these serious infections. M-L Phase III Interim Efficacy Q2 ‘21. Market Opportunity – Prescription Hemorrhoid Product: We believe the $2 billion worldwide market... CITI-002 –Halo-Lido: ... We expect to file an IND in Q2 2021 and initiate the phase 2b trial in Q3 2021.
Leonard Mazur, Chairman of Citius Pharmaceuticals (NASDAQ:CTXR) Interviewed on CEORoadshow June 10, 2021
Citius Pharma (CTXR) Prepares for Phase III Data Release at the End of This Month and the Potential Catalysts are Lining Up. June 15, 2021 Highlights Entering the Russell 2000 Index Cash Horde in the Bank Late-stage Phase 3 data release in two weeks https://tradersnewssource.com/citiu...th-and-the-potential-catalysts-are-lining-up/
Citius: Halt For Superiority On The Horizon Jun. 15, 2021 North Shore Research Summary IDMC meets on June 29 for Superiority review. Mino-Lok has no competition. Price target increased to $10. Mino-Lok has Fast Track designation. Enough cash through commercialization. https://seekingalpha.com/article/4434912-citius-halt-for-superiority-on-the-horizon
Investors brace for annual Russell index rebalancing with pandemic imprint June 18, 2021 NEW YORK, June 18 (Reuters) - Market participants are girding for probably the biggest trading event of the year next Friday, as FTSE Russell stages the final reconstitution of its indexes, and trillions of dollars in investments could be influenced by the event that will reflect a wild trading year marked by the pandemic and the “meme” stock craze. https://www.reuters.com/business/in...rebalancing-with-pandemic-imprint-2021-06-18/
https://dawsonjames.com/wp-content/uploads/2021/06/CTXR.6.9.21.pdf Valuation. Our valuation is based on our therapeutic models and associated assumptions projected to 2028. The lead product, Mini-Lok, is now in a Phase 3 trial. We conservatively assume just 50% probability of success in our models. On top of this, we also use a 30% risk rate in our free cash flow to the firm (FCFF), our discounted EPS (dEPS) and sum-of-the-parts (SOP) models. We equal weight and average these metrics and then round to the nearest whole number to derive our $8.00 price target. Should go much higher once data is provided and positive. Big short interest, I expect a big squeeze here.
I hope DMC stops the study, it's not ethical to continue when you have such good results. Hope to see FDA approval Q4.
I believe we'll see big movements before the inclusion in Russell 2000 index. People will front-run it no doubt. This in combination with the results early july should be able to send this one somewhere between $5-$8 minimum.
Thanks for the tip! I will be adding to my "watchlist" It makes me a little nervous that they have been in phase 3 trials with Mino-Lok for so damn long though. Especially for a trial that reportedly only needs 144 participants.
Unfortunately the trial was not halted early but will continue as planned. Sold my shares today and realized the gain of 200%. Obviously it could have been more if I would have played it save... Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned July 01, 2021 https://ir.citiuspharma.com/press-releases/detail/151/citius-pharmaceuticals-inc-announces-positive
@ 99 cents in the past year... managed to sell at $3 bucks today... bad luck with the decision today...
